Oral Cannabidiol in the Treatment of Myofascial Pain Disorder of the Temporomandibular Region: A Placebo-Controlled Randomized Clinical Trial.

Med Cannabis Cannabinoids · 2026 · PMC13095194 · PMID 42016900

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

a nonsignificant trendp = 0.10so close (0.05 < p ≤ 0.1)

There was a nonsignificant trend towards a reduction in median VAS pain in the CBD group across timepoints ( p = 0.10), but not the placebo group ( p = 0.20) ( Table 3 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.